Convatec Group PLC (LON:CTEC – Get Free Report) hit a new 52-week high during mid-day trading on Monday. The stock traded as high as GBX 259.80 and last traded at GBX 258, with a volume of 8,874,752 shares changing hands. The stock had previously closed at GBX 257.40.
Wall Street Analyst Weigh In
CTEC has been the subject of a number of analyst reports. Royal Bank Of Canada restated an “outperform” rating and issued a GBX 315 price target on shares of Convatec Group in a research report on Monday, August 3rd. Jefferies Financial Group reaffirmed a “buy” rating and issued a GBX 300 price target on shares of Convatec Group in a research note on Wednesday, August 5th. Berenberg Bank decreased their price objective on shares of Convatec Group from GBX 340 to GBX 335 and set a “buy” rating for the company in a report on Friday, September 11th. Deutsche Bank reissued a “buy” rating and issued a GBX 315 price objective on shares of Convatec Group in a research report on Wednesday, August 5th. Finally, Peel Hunt restated an “add” rating and issued a GBX 270 target price on shares of Convatec Group in a research note on Tuesday, August 4th. Eight analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of GBX 305.44.
Get Our Latest Stock Report on Convatec Group
Convatec Group Price Performance
Insider Buying and Selling at Convatec Group
In other news, insider Jens Viebke acquired 24,400 shares of the firm’s stock in a transaction that occurred on Tuesday, October 13th. The stock was purchased at an average cost of GBX 230 per share, for a total transaction of £56,120. 1.00% of the stock is owned by insiders.
Convatec Group Company Profile
ConvaTec Group PLC engages in the development, manufacturing, and sale of medical products, services, and technologies in Europe, North America, and internationally. The company offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostomy care solutions, including devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, and bladder cancer.
Further Reading
- Five stocks we like better than Convatec Group
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Convatec Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Convatec Group and related companies with MarketBeat.com's FREE daily email newsletter.
